Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Octreotide pamoate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Octreotide pamoate | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Octreotide pamoate | DRUG | - |
Inclusion criteria: * Male or female from 18-60 years of age, cholecystectomized at least 4 months prior to the start of the study. * In a good health as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests at screening * Body mass index with...
Octreotide pamoate is an investigational long-acting formulation of octreotide, a small molecule somatostatin receptor agonist developed by Novartis AG. It is designed as an extended-release depot version of octreotide. The specific clinical indications for this pamoate formulation have not been disclosed. It remains in Phase 1 clinical development.
Octreotide pamoate targets somatostatin receptors SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5, acting as an agonist at these receptors. Its pharmacologic activity is mediated through binding and activating these G protein-coupled receptors, with highest affinity typically associated with SSTR2 and SSTR5.
Octreotide pamoate is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis is the sponsor responsible for the clinical development of this extended long-acting formulation.
Octreotide pamoate is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The only recorded trial is a completed Phase 1 study in healthy volunteers.
Octreotide pamoate has been studied in one completed Phase 1 trial, NCT00432068, titled an open label study of a single dose of a new extended long acting formulation of octreotide pamoate in healthy volunteers. It enrolled 48 healthy cholecystectomized participants across Belgium, France, and Italy. No active trials are ongoing.
Octreotide pamoate is a distinct long-acting pamoate salt formulation of octreotide, not identical to immediate-release octreotide. It is being developed as an extended-release depot version. The active moiety is octreotide, but the pamoate salt alters its release profile.